A method for preparing a CSF-1R inhibitor intermediate or its acid salt

Through the three-step reaction method, the iron powder reduction method is avoided, the yield and purity of the CSF-1R inhibitor intermediate is improved, the problems of low middle yield and environmental pollution in the prior art are solved, and it is suitable for industrial production.

CN115385896BActive Publication Date: 2024-11-15ABBISKO THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210564607.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-05-24
Filing Date
2022-05-23
Publication Date
2024-11-15
Estimated Expiration
2042-05-23

AI Technical Summary

Technical Problem

The existing preparation methods for CSF-1R inhibitor intermediates have low yields, and the iron powder reduction method causes environmental pollution, which is not suitable for industrial applications.

Method used

The three-step reaction method is adopted, including compound condensation, ammonization and reaction under alkaline conditions. The compound of formula (3) is formed by condensation under alkaline conditions, followed by reaction with compound of formula (4), and finally react with CF3CONH2 to form CSF-1R inhibition The agent intermediate or its acid salt avoids the iron powder reduction method and uses an inorganic base and a catalyst to react.

Benefits of technology

The yield rate is improved, and the total yield reaches 60%, solving the problem of insufficient yield rate in the prior art, reducing environmental pollution, suitable for industrial production, and providing stable intermediates for drug preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115385896B_ABST
    Figure CN115385896B_ABST
Patent Text Reader

Abstract

The present invention relates to a method for preparing a CSF-1R inhibitor intermediate or an acid salt thereof. The preparation method uses 2-chloro-4-fluoropyridine or an acid salt thereof as a raw material and prepares the intermediate through three-step reactions. The preparation method of the present invention has readily available raw materials, is simple to operate, has a greatly improved yield in each step compared to the prior art, and has a stable process, can meet the needs of industrial production, solves the problem of drug accessibility, and is conducive to accelerating the clinical development and drug marketing of CSF-1R inhibitors. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of drug synthesis, and specifically relates to a method for preparing a CSF-1R inhibitor intermediate or an acid salt thereof. Background Art

[0002] The full name of CSF-1R is colony stimulating factor-1 receptor. This receptor is a membrane protein expressed on the surface of macrophages and monocytes. Its extracellular segment can bind to macrophage colony stimulating factor, and the intracellular tyrosine kinase can activate the downstream cell growth and reproduction signaling pathways of macrophages and monocytes. Therefore, the CSF-1R signaling pathway has an important influence on the development and differentiation of macrophages and monocytes, as well as the physiological functions of tumor-associated macrophages (TAM). With the progress of tumor immunotherapy in recent years, tumor-associated macrophages (TAM) and myeloid-derived suppressor cells (MDSC) are considered to be directly related to the formation of the immunosuppressive microenvironment inside the tumor and the angiogenesis that supports tumor growth. At the same time, clinical studies have shown that the content of TAM is negatively correlated with the prognosis of tumor patients. In vivo efficacy experiments in mice have shown that inhibiting the CSF-1R signaling pathway can significantly reduce the number of macrophages that suppress the immune system inside the tumor and increase the content of CD8-positive T cells. These experimental results suggest that CSF-1R small molecule inhibitors may reverse the immunosuppressive environment within the tumor, promote the activation of the immune system, and prolong the lives of cancer patients.

[0003] In 2018, Shanghai Heyu Biopharmaceutical Co., Ltd. disclosed a series of compounds with selective CSF-1R inhibitory effects in WO2018214867A1. The application also disclosed a series of intermediates, whose general structural formula is as follows:

[0004]

[0005] Among them, an intermediate used in the compound of Example 1 of the application has the following chemical structure: Its Chinese name is: 6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine. The preparation of this intermediate is based on 5-bromo-6-substituted pyridin-2-amine raw material and is obtained through four steps of reaction. The synthetic route is as follows:

[0006]

[0007] The yields of steps 1) and 2) of the synthesis method are very low, only 45% and 37.8% respectively, and the total yield of the four-step reaction is 13.6%. In addition, the last step of the reaction adopts an iron powder reduction method, which is difficult to filter during the post-treatment process. The iron mud and wastewater containing aromatic amine produced seriously pollute the environment, and there are serious technical defects, which are not suitable for industrial application. Therefore, it is urgent to develop a preparation method of the compound of formula (A) for industrial production, and to prepare qualified API to meet the production needs of clinical research and marketed drug preparations. Summary of the invention

[0008] The object of the present invention is to provide a method for preparing a CSF-1R inhibitor intermediate or its acid salt, so as to meet the production needs of clinical research and marketed pharmaceutical preparations.

[0009] The first aspect of the present invention provides a method for preparing a compound of formula (A) or an acid salt thereof, comprising the following synthesis steps:

[0010] Step 1) the compound of formula (1) or its acid salt and the compound of formula (2) or its acid salt are condensed under alkaline conditions to generate the compound of formula (3) or its acid salt;

[0011] Step 2) reacting the compound of formula (3) or its acid salt with the compound of formula (4) or its acid salt under alkaline conditions to generate the compound of formula (5) or its acid salt;

[0012] Step 3) The compound of formula (5) or its acid salt is aminated under alkaline conditions to generate the compound of formula (A) or its acid salt; the reaction scheme is as follows:

[0013]

[0014] In each formula, R1 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents;

[0015] R2 is selected from hydrogen, deuterium, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents;

[0016] The "heterocyclic group" contains 1-2 heteroatoms selected from nitrogen atoms or oxygen atoms.

[0017] As a preferred embodiment, in the preparation method, R1 is selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, hydroxyl, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, oxetanyl, tetrahydrofuranyl, methoxy, ethoxy, isopropoxy, carboxyl and amino;

[0018] R2 is selected from the group consisting of hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, ethyl, isopropyl, cyclopropyl and cyclobutyl.

[0019] As a further preferred embodiment, in the preparation method, R1 is selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, methoxymethyl, hydroxymethyl, ethyl, methoxyethyl, hydroxyethyl, n-propyl, isopropyl, n-butyl, hydroxy-substituted isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, morpholinylethyl, pyrrolyl, methyl-substituted pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl;

[0020] R2 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, trifluoromethyl and trideuteriomethyl.

[0021] As a further preferred embodiment, in step 2) of the preparation method, the molar ratio of the compound of formula (3) or its acid salt to the compound of formula (4) or its acid salt is 1:(0.2-5).

[0022] As a further preferred embodiment, in step 2) of the preparation method, the molar ratio of the compound of formula (3) or its acid salt to the compound of formula (4) or its acid salt is 1:(0.5-3).

[0023] As a further preferred embodiment, in step 2) of the preparation method, the molar ratio of the compound of formula (3) or its acid salt to the compound of formula (4) or its acid salt is 1:(0.8-2).

[0024] As a further preferred embodiment, step 2) in the preparation method is carried out under alkaline conditions, the alkaline conditions are an inorganic base system, and the inorganic base is selected from K2CO3, KHCO3, Cs2CO3, Na2CO3 or NaHCO3.

[0025] As a further preferred embodiment, in step 3) of the preparation method, the compound of formula (5) or its acid salt reacts with CF3CONH2 at a molar ratio of 1:(0.5-20).

[0026] As a further preferred scheme, in step 3) of the preparation method, the compound of formula (5) or its acid salt reacts with CF3CONH2 at a molar ratio of 1:(1-10).

[0027] As a further preferred scheme, in step 3) of the preparation method, the compound of formula (5) or its acid salt reacts with CF3CONH2 in a molar ratio of 1:(2-5).

[0028] As a further preferred embodiment, in the preparation method, step 3) is carried out under alkaline conditions, the alkaline conditions are an inorganic base system, and the inorganic base is selected from K2CO3, KHCO3, Cs2CO3, Na2CO3 or NaHCO3.

[0029] As a further preferred embodiment, step 3) in the preparation method is carried out under the catalysis of a catalyst, and the catalyst is CuI.

[0030] As a further preferred embodiment, step 1) in the preparation method is carried out under alkaline conditions, the alkaline conditions are an inorganic base system, and the inorganic base is selected from K2CO3, KHCO3, Cs2CO3, Na2CO3 or NaHCO3.

[0031] As a further preferred embodiment, in step 1) of the preparation method, Pd(dppf)Cl2 is used as a condensation agent.

[0032] As a preferred embodiment, the acid salt in the preparation method includes an inorganic acid salt or an organic acid salt.

[0033] As a further preferred embodiment, the inorganic acid salt is selected from hydrochloride, sulfate, hydrobromide, hydrofluoride, hydroiodide or phosphate.

[0034] As a further preferred embodiment, the organic acid salt is selected from acetate, dichloroacetate, trichloroacetate, trifluoroacetate, benzenesulfonate, p-toluenesulfonate, 4-chlorobenzenesulfonate, 1,5-naphthalene disulfonate, naphthalene-2-sulfonate, ethane-1,2-disulfonate, methanesulfonate, ethanesulfonate, benzoate, caprate, hexanoate, caprylate, cinnamate, citrate, cyclohexanesulfamic acid salt, camphorsulfonate, aspartate, camphorate, gluconate, glucuronate, glutamate, isoascorbate, lactate, malate, mandelate, pyroglutamate, tartrate, dodecyl sulfate, dibenzoyl tartaric acid or succinate.

[0035] The second aspect of the present invention provides a compound of formula (5):

[0036]

[0037] Wherein, R1 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents;

[0038] R2 is selected from hydrogen, deuterium, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents;

[0039] The "heterocyclic group" contains 1-2 heteroatoms selected from nitrogen atoms or oxygen atoms.

[0040] As a preferred embodiment, in the compound of formula (5), R1 is selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, hydroxyl, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, oxetanyl, tetrahydrofuranyl, methoxy, ethoxy, isopropoxy, carboxyl and amino.

[0041] R2 is selected from the group consisting of hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, ethyl, isopropyl, cyclopropyl and cyclobutyl.

[0042] As a preferred embodiment, in the compound of formula (5), R1 is selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, methoxymethyl, hydroxymethyl, ethyl, methoxyethyl, hydroxyethyl, n-propyl, isopropyl, n-butyl, hydroxy-substituted isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, morpholinylethyl, pyrrolyl, methyl-substituted pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl;

[0043] R2 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, trifluoromethyl and trideuteriomethyl.

[0044] As a preferred embodiment, the compound of formula (5) has the compound structure of formula (5'):

[0045]

[0046] The third aspect of the present invention provides a compound of formula (1'), a compound of formula (2') or a compound of formula (3'):

[0047]

[0048] Wherein, R1 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents;

[0049] R2 is selected from hydrogen, deuterium, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4Substituted by alkoxy, carboxyl and amino substituents;

[0050] The "heterocyclic group" contains 1-2 heteroatoms selected from nitrogen atoms or oxygen atoms.

[0051] As a preferred embodiment, in the compound of formula (1'), the compound of formula (2') or the compound of formula (3'), R1 is selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, hydroxyl, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, oxetanyl, tetrahydrofuranyl, methoxy, ethoxy, isopropoxy, carboxyl and amino;

[0052] R2 is selected from the group consisting of hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, ethyl, isopropyl, cyclopropyl and cyclobutyl.

[0053] As a preferred embodiment, in the compound of formula (1'), formula (2') or formula (3'), R1 is selected from hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, methoxymethyl, hydroxymethyl, ethyl, methoxyethyl, hydroxyethyl, n-propyl, isopropyl, n-butyl, hydroxy-substituted isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, morpholinylethyl, pyrrolyl, methyl-substituted pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl;

[0054] R2 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, trifluoromethyl and trideuteriomethyl.

[0055] Compared with the prior art, the present invention has the following technical advantages:

[0056] 1. In terms of environmental protection, the present invention uses iodine to replace the intermediate amination in step 2), avoiding the use of iron powder reduction method, which greatly reduces environmental pressure.

[0057] 2. On the technical level, the present invention adopts a three-step reaction to obtain the compound of formula (A), and the yield of each step of the reaction is relatively high. The total yield of the three steps reaches 60%, which solves the drug accessibility problem of the prior art that requires four steps of reaction and the yield is less than 15%. In addition, the products of each step of the present invention have high purity and good stability, which is conducive to industrial application.

[0058] 3. In terms of operation, the raw materials or reagents used in the present invention are simple and easy to obtain, the reaction conditions are mild, the operability is strong, and column chromatography technology is not used in the entire preparation process, which is suitable for industrial production.

[0059] 4. The process route of the present invention also provides a new iodine-substituted intermediate, which has high stability and can be used to prepare the compound of formula (A) or its acid salt.

[0060] 5. The process route of the present invention also provides an acid salt of the compound of formula (A), preferably a trifluoroacetate, a hydrochloride or a hydroiodide. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 The HPLC spectrum of the product synthesized in the third step of the specific embodiment is shown in FIG. DETAILED DESCRIPTION

[0062] The inventors of the present application have developed a method for preparing a CSF-1R inhibitor intermediate or its acid salt after extensive and in-depth research. The preparation method uses 2-chloro-4-fluoropyridine as a raw material and is prepared by three steps. The preparation method of the present invention is simple to operate, has a high yield in each step, and has a stable process. It can meet the needs of industrial production, solve the problem of drug accessibility, and is conducive to accelerating the clinical development and drug marketing of CSF-1R inhibitors. On this basis, the present invention is completed.

[0063] The present invention is further described in detail and completely below in conjunction with the embodiments, but the present invention is by no means limited to the contents of the embodiments.

[0064] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR). The NMR chemical shift (δ) is given in parts per million (ppm). The NMR is measured using a Bruker BioSpin Gmbh 600 nuclear magnetic resonance spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD) and deuterated chloroform (CDCl3) as the measuring solvent, and tetramethylsilane (TMS) as the internal standard.

[0065] The thin layer chromatography silica gel plate used was Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate, and the specification used by TLC was 0.15 mm to 0.20 mm.

[0066] The purity of the compound of the present invention is detected by Agilent high performance liquid chromatography (HPLC). Chromatographic column: Waters C18. Mobile phase A: 0.05% trifluoroacetic acid in water, mobile phase B: 0.05% trifluoroacetic acid in acetonitrile. Flow rate: 1.0 mL / min. Detection wavelength: 254 nm.

[0067] The starting materials in the examples of the present invention are known and can be purchased on the market, or can be synthesized by or according to methods known in the art.

[0068] Unless otherwise specified, all reactions of the present invention are carried out under a dry nitrogen or argon atmosphere, the solvent is a dry solvent, and the reaction temperature is in degrees Celsius (°C). Specific embodiments

[0070] Step 1: Synthesis of 4-fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine

[0071]

[0072] Isopropanol (24 L, 316.2 mol), 2-chloro-4-fluoropyridine (4.0 kg, 30.4 mol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxin-2-yl)-1H-pyrazole (6.64 kg, 31.9 mol), K2CO3 (12.17 kg, 88.1 mol), water (1.2 kg, 66.7 mol) and Pd(dppf)Cl2 (111.3 g, 0.15 mol) were added under nitrogen protection, the reaction mixture was heated to 80-90°C, stirred for 12 hours, TLC detected that the reaction of the raw materials was complete, the reaction solution was cooled to 50°C, acetylcysteine ​​(400 ml) was added, stirring was continued for 1 hour, the reaction solution was cooled to 20°C, water (10 L) was added, the organic phase was separated and concentrated to dryness. Toluene (10 L) and water (10 L) were added to the residue, hydrochloric acid was added to adjust the pH value to 1, the layers were separated, the aqueous phase was extracted with ethyl acetate, Na2CO3 was added to the aqueous phase to adjust the pH value to 9, and then extracted with ethyl acetate (12 L*3), the organic phases were combined, concentrated to dryness, methyl tert-butyl ether (10 L) was added, filtered, and the filter cake was dried to obtain 4.3 kg (yield: 79.63%, purity: 99.74%) of 4-fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine.

[0073] Step 2: Synthesis of 6-iodo-2-methyl-3-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine

[0074]

[0075] Under nitrogen protection, add N-methylpyrrolidone (150mL, 1.56mol), 4-fluoro-2-(1-methyl-1H-pyrazol-4-yl)pyridine (39.58g, 0.22mol), 6-iodo-2-methylpyridin-3-ol (50.0g, 0.21mol) and Na2CO3 (45.1g, 0.43mol), heat the reaction mixture to 100-110°C, stir and react for 60 hours, TLC detection shows that the reaction of the raw materials is complete, cool the reaction solution to room temperature, add ethanol (300ml), and continue stirring for 10 minutes. The reaction solution was added dropwise to 500 mL of water while controlling the temperature below 35°C, and stirring was continued for 2 hours. The mixture was filtered and the filter cake was dried to obtain 71.73 g of 6-iodo-2-methyl-3-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine (yield: 82%, purity: 99.46%).

[0076] ESI[M+H] + 393.2.

[0077] 1 HNMR(DMSO-d6)δ8.39(d,J=8.0,1H),8.28(s,1H),7.99(s,1H),7.75(d,J=8.0,1H),7.32 (d, J = 8.0, 1H), 7.24 (d, J = 8.0, 1H), 6.69 (dd, J = 5.6, 2.4, 1H), 3.86 (s, 3H), 2.34 (s, 3H).

[0078] Step 3: Synthesis of 6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine

[0079]

[0080] Under nitrogen protection, 1,4-dioxane (300 mL, 3.39 mol), dimethylformamide (35 mL, 0.42 mol), 6-iodo-2-methyl-3-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridine (50 g, 0.13 mol), CF3CONH2 (50.44 g, 0.45 mol), K2CO3 (61.6 g, 0.45 mol), CuI (1.21 g, 0.006 mol) and dimethylethylenediamine (5.62 g, 0.064 mol), heat the reaction mixture to 100-110 ° C, stir and react for 1 hour, cool the reaction solution to 70 ° C, add 150 ml of pure water, continue stirring for 1 hour, concentrate the reaction mixture under reduced pressure to 100-150 mL, cool the reaction solution to room temperature, add 20-30% (w / w) NH3 .H2O (30mL), water (300mL), continue stirring for 1 hour, extract with dichloromethane (800mL*2), separate the liquids, extract the aqueous phase with dichloromethane (400mL), combine the organic phases, wash 3 times with saturated brine (100mL*3), control the temperature at 40°C and concentrate under reduced pressure to a volume of 100-150mL, add methyl tert-butyl ether (250mL), beat and stir for 2 hours, filter, and dry the filter cake to obtain 33.2g of 6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine (yield 92.2%, purity: 94.53%, HPLC spectrum see attached Figure 1 ).

[0081] MS m / z(ESI):282[M+H] + .

[0082] From the attached Figure 1 It can be seen that the crude purity of the target product of this step, 6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-amine, is 94.53%. The crude product contains a small amount of impurities. After chromatographic analysis, the chemical structure of the main impurities is as follows:

[0083]

[0084] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as references separately. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope of the present invention.

Claims

1. A method for preparing a compound of formula (A) or an acid salt thereof, characterized in that: The steps include: Step 1) the compound of formula (1) or its acid salt and the compound of formula (2) or its acid salt are condensed under alkaline conditions to generate the compound of formula (3) or its acid salt; Step 2) reacting the compound of formula (3) or its acid salt with the compound of formula (4) or its acid salt under alkaline conditions to generate the compound of formula (5) or its acid salt; Step 3) ammoniation of the compound of formula (5) or its acid salt under alkaline conditions to generate the compound of formula (A) or its acid salt; In each formula, R1 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents; R2 is selected from hydrogen, deuterium, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents; The "heterocyclic group" contains 1-2 heteroatoms selected from nitrogen atoms or oxygen atoms.

2. The preparation method according to claim 1, characterized in that: R1 is selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl, which are optionally further substituted with one or more substituents selected from deuterium, hydroxyl, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, oxetanyl, tetrahydrofuranyl, methoxy, ethoxy, isopropoxy, carboxyl and amino; R2 is selected from the group consisting of hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, ethyl, isopropyl, cyclopropyl and cyclobutyl.

3. The preparation method according to claim 1, characterized in that: R is selected from the group consisting of hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, methoxymethyl, hydroxymethyl, ethyl, methoxyethyl, hydroxyethyl, n-propyl, isopropyl, n-butyl, hydroxy-substituted isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, morpholinylethyl, pyrrolyl, methyl-substituted pyrrolyl, piperazinyl, oxetanyl, and tetrahydrofuranyl; R2 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, trifluoromethyl and trideuteriomethyl.

4. The preparation method according to claim 1, characterized in that: In the step 2), the molar ratio of the compound of formula (3) or its acid salt to the compound of formula (4) or its acid salt is 1:(0.2-5).

5. The preparation method according to claim 1, characterized in that: In the step 2), the molar ratio of the compound of formula (3) or its acid salt to the compound of formula (4) or its acid salt is 1:(0.5-3).

6. The preparation method according to claim 1, characterized in that: In the step 2), the molar ratio of the compound of formula (3) or its acid salt to the compound of formula (4) or its acid salt is 1:(0.8-2).

7. The preparation method according to claim 1, characterized in that: The step 2) is carried out under alkaline conditions, the alkaline conditions are an inorganic base system, and the inorganic base is selected from K2CO3, KHCO3, Cs2CO3, Na2CO3 or NaHCO3.

8. The preparation method according to claim 1, characterized in that: In the step 3), the compound of formula (5) or its acid salt reacts with CF3CONH2, and the molar ratio of the feed is 1:(0.5-20).

9. The preparation method according to claim 1, characterized in that: In the step 3), the compound of formula (5) or its acid salt reacts with CF3CONH2, and the molar ratio of the feed is 1:(1-10).

10. The preparation method according to claim 1, characterized in that: In the step 3), the compound of formula (5) or its acid salt reacts with CF3CONH2, and the molar ratio of the feed is 1:(2-5).

11. The preparation method according to claim 1, characterized in that: The step 3) is carried out under alkaline conditions, the alkaline conditions are an inorganic base system, and the inorganic base is selected from K2CO3, KHCO3, Cs2CO3, Na2CO3 or NaHCO3.

12. The preparation method according to claim 1, characterized in that: The step 3) is carried out under the catalysis of a catalyst, and the catalyst is CuI.

13. The preparation method according to claim 1, characterized in that: The step 1) is carried out under alkaline conditions, the alkaline conditions are an inorganic base system, and the inorganic base is selected from K2CO3, KHCO3, Cs2CO3, Na2CO3 or NaHCO3.

14. The preparation method according to claim 1, characterized in that: In the step 1), Pd(dppf)Cl2 is used as a condensation agent.

15. The preparation method according to claim 1, characterized in that: The acid salt includes an inorganic acid salt or an organic acid salt; the inorganic acid salt is selected from hydrochloride, sulfate, hydrobromide, hydrofluoride, hydroiodide or phosphate; the organic acid salt is selected from acetate, dichloroacetate, trichloroacetate, trifluoroacetate, benzenesulfonate, p-toluenesulfonate, 4-chlorobenzenesulfonate, 1,5-naphthalene disulfonate, naphthalene-2-sulfonate, ethane-1,2-disulfonate, methanesulfonate, ethanesulfonate, benzoate, decanoate, hexanoate, caprylate, cinnamate, citrate, cyclohexanesulfamic acid salt, camphorsulfonate, aspartate, camphorate, gluconate, glucuronate, glutamate, isoascorbate, lactate, malate, mandelate, pyroglutamate , tartrate, dodecyl sulfate, dibenzoyl tartrate, formate, fumarate, galactonate, gentisate, acetohydroxamate, malonate, succinate, glutarate, adipate, sebacate, 2-ketoglutarate, glycolate, hippurate, isethionate, lactobionate, ascorbate, aspartate, laurate, maleate, nicotinate, oleate, orotate, oxalate, palmitate, pamoate, propionate, 4-acetamidobenzoate, 4-aminobenzoate, salicylate, 4-aminosalicylate, 2,5-dihydroxybenzoate, 1-hydroxy-2-naphthoate, stearate, thiocyanate, undecylenate, or succinate.

16. Compound of formula (5): in, R1 is selected from hydrogen, deuterium, C 1-4 Alkyl, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents; R2 is selected from hydrogen, deuterium, C 1-4 Alkyl and C 3-6 Cycloalkyl, the above groups are optionally further substituted with one or more selected from deuterium, hydroxyl, halogen, cyano, C 1-4 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group, C 1-4 Substituted by alkoxy, carboxyl and amino substituents; The "heterocyclic group" contains 1-2 heteroatoms selected from nitrogen atoms or oxygen atoms.

17. The compound of formula (5) according to claim 16, characterized in that R1 is selected from hydrogen, deuterium, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, piperazinyl, oxetanyl and tetrahydrofuranyl, which are optionally further substituted with one or more substituents selected from deuterium, hydroxyl, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, morpholinyl, pyrrolyl, oxetanyl, tetrahydrofuranyl, methoxy, ethoxy, isopropoxy, carboxyl and amino; R2 is selected from the group consisting of hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, ethyl, isopropyl, cyclopropyl and cyclobutyl.

18. The compound of formula (5) according to claim 16, characterized in that R is selected from the group consisting of hydrogen, deuterium, methyl, trifluoromethyl, trideuteriomethyl, methoxymethyl, hydroxymethyl, ethyl, methoxyethyl, hydroxyethyl, n-propyl, isopropyl, n-butyl, hydroxy-substituted isobutyl, tert-butyl, sec-butyl, cyclopropyl, cyclobutyl, morpholinyl, morpholinylethyl, pyrrolyl, methyl-substituted pyrrolyl, piperazinyl, oxetanyl, and tetrahydrofuranyl; R2 is selected from the group consisting of hydrogen, deuterium, methyl, ethyl, trifluoromethyl and trideuteriomethyl.

19. The compound of formula (5) according to claim 16, characterized in that The compound of formula (5) has the compound structure of formula (5'):